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Abstract
Background: Inflammatory breast cancer (IBC) had been perceived to have a poor prognosis.
Oncologists were not enthusiastic in the past to give aggressive treatment. Single institution studies
tend to have small patient numbers and limited years of follow-up. Most studies do not report 10-
, 15- or 20-year results.
Methods:  Data was obtained from the population-based database of the Surveillance,
Epidemiology, and End Results program of the National Cancer Institute from 1975–1995 using
SEER*Stat5.0 software. This period of 21 years was divided into 7 periods of 3 years each. The
years were chosen so that there was adequate follow-up information to 2000. ICD-O-2 histology
8530/3 was used to define IBC. The lognormal model was used for statistical analysis.
Results: A total of 1684 patients were analyzed, of which 84% were white, 11% were African
Americans, and 5% belonged to other races. Age distribution was < 30 years in 1%, 30–40 in 11%,
40–50 in 22%, 50–60 in 24%, 60–70 in 21%, and > 70 in 21%. The lognormal model was validated
for 1975–77 and for 1978–80, since the 10-, 15- and 20-year cause-specific survival (CSS) rates,
could be calculated using the Kaplan-Meier method with data available in 2000. The data were then
used to estimate the 10-, 15- and 20-year CSS rates for the more recent years, and to study the
trend of improvement in survival. There were increasing incidences of IBC: 134 patients in the
1975–77 period to 416 patients in the 1993–95 period. The corresponding 20-year CSS increased
from 9% to 20% respectively with standard errors of less than 4%.
Conclusion: The improvement of survival during the study period may be due to introduction of
more aggressive treatments. However, there seem to be no further increase of long-term CSS,
which should encourage oncologists to find even more effective treatments. Because of small
numbers of patients, randomized studies will be difficult to conduct. The SEER population-based
database will yield the best possible estimate of the trend in improvement of survival for patients
with IBC.
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Background
Inflammatory breast cancer (IBC) occurs rarely [1]. Signs
and symptoms of this condition include the presence of
erythema, edema or peau d'orange appearance of the skin,
and other clinical signs of disease. Diagnosis is made by
skin biopsy. The definition of IBC varies in the literature
and leads to some disparities. In this study, the patholog-
ical definition is used.
It is known that IBC have a poor prognosis. Oncologists
were not enthusiastic to administer aggressive treatment
in the past. Nowadays, treatment for this aggressive form
of breast cancer is multi-modal, and includes chemother-
apy, surgery, radiation therapy, and hormonal therapy
[2]. The optimal sequence of the different modalities is
still a subject of research [3]. Development of novel ther-
apeutic agents continues and is based on an expanding
understanding of the biology of tumor development and
progression. Advances in treatment continue to improve
the prognosis for this disease [4]. With a few notable
exceptions, many publications on IBC do not have long
periods of follow-up [5,6]. These single-institution studies
are from academic centers. To our knowledge, long-term
results of cases treated in the community are not available.
This study examines the changes in the prognosis of IBC
over the years with the Surveillance, Epidemiology, and
End Results (SEER) database [7].
There is a parametric lognormal model, proposed by Boag
[8-10] that has been validated retrospectively in the liter-
ature, and can be used prospectively for predicting long-
term survival rates several years earlier than would other-
wise be possible using the Kaplan-Meier method of calcu-
lation [11].
Boag's lognormal model for long-term cancer survival
rates has been available for use for some 50 years. When
the lognormal model was first proposed in the 1940s, it
was difficult to implement because of a lack of computing
power, and lack of good quality long-term follow-up data
from cancer registries. Since 1970s the model has been
used by authors on breast cancer, cervix uteri cancer, head
and neck cancer, intraocular melanoma, choroidal-ciliary
body melanoma, and small cell lung cancer [12-17]. Cur-
rently, although available computing power is adequate,
good quality follow-up data on a sufficient number of
patients are seldom available, and so can limit the appli-
cation of Boag's model. Studies from single institutions
tend to have small number of patients and limited years
of follow-up for IBC. Use of a large data registry such as
the SEER database with good long-term follow-up data
can overcome these potential limitations.
Methods
From the population database of the Surveillance, Epide-
miology, and End Results program of the National Cancer
Institute from 1975–1995, data were extracted using
SEER*Stat5.0 software from the 9 registries: San Fran-
cisco-Oakland, Connecticut, Metropolitan Detroit,
Hawaii, Iowa, New Mexico, Seattle (Puget Sound), Utah,
and Metropolitan Atlanta. This period of 21 years was
divided into 7 periods of 3 years each. The years of diag-
nosis were 1975–77, 1978–80, 1981–83, 1984–86,
1987–89, 1990–92, and 1993–95. These years were cho-
sen so as to provide adequate follow-up information to
2000. ICD-O-2 histology 8530/3 was used to define IBC.
The data used in the study were survival time, vital status,
and cause of death.
The cause-specific survival (CSS) was defined as the inter-
val from the date of diagnosis to the date of death from
breast cancer or to the last follow-up date for censoring
purposes, if the patient was alive and was still being fol-
lowed at the time of data cut-off.
The lognormal model was used for statistical analysis.
Using short-term follow-up data, the lognormal model
can predict long-term survival rates comparable in accu-
racy with those calculated by the Kaplan-Meier method
using long-term follow-up [18]. The assumption of the
lognormal model is that the survival times of the patients
died of a specific cancer follows a lognormal distribution.
What lognormal distribution means is that it becomes a
normal distribution when the variables are converted by
taking logarithmic transformation. The lognormal model
has three parameters: the standard deviation S, the mean
M and the proportion cured C. The proportion cured is
defined as the portion of all the patients treated remaining
alive and symptom free for a long period, some of those
who died of intercurrent diseases are presumably cured of
the cancer. This lognormal model used a maximum likeli-
hood method to estimate long-term CSS (e.g., 10-year,
15-year and 20-year survival rates) from only short-term
follow-up data. The CSS rates at time τ is calculated as [C+
(1-C)·Q]·100%, where C is the proportion cured of
patients and Q is the integral of the lognormal distribu-
tion between the limits of time τ and infinity.
The long-term survival rates were predicted by Boag's
method using a computer program run by Microsoft
Excel. In this parametric lognormal model, the standard
deviation S was fixed; only the two remaining parameters,
mean M and proportion cured C, were kept floating when
using the maximum likelihood method. A range (0.35–
0.55) of S with step 0.01 was tested. The value of S was
chosen for the best fit to the first five years known survival
curve obtained by the Kaplan-Meier method, and alsoBMC Cancer 2005, 5:137 http://www.biomedcentral.com/1471-2407/5/137
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multiple iterations converged to a stable solution for M
and C. The parameters obtained are shown in Table 1.
A 3-year period of diagnosis was selected and patients
were followed as a cohort for an additional 3 years. For
example, for cases diagnosed during the 3-year period,
1975–1977, prediction of the long-term survival rates was
made using follow-up data to December 31, 1980 (i.e., 3
years after 1977). The predicted long-term survival rates
for patients diagnosed during 1975–1977, and 1978–
1980 were compared to the Kaplan-Meier estimates.
Confidence intervals are calculated by +/- 1.96 (standard
error), assuming that the errors are normally distributed.
Results
A total of 1684 patients were extracted from the SEER
database: 84% were white, 11% were African-Americans,
and 5% belonged to other races. Age distribution was < 30
years in 1%, 30–40 in 11%, 40–50 in 22%, 50–60 in 24%,
60–70 in 21%, and > 70 in 21%. Table 2 shows the patient
characteristics of the 7 periods in the study.
The proportions cured as shown in Table 1 for the differ-
ent periods are almost linearly increasing (correlation
coefficient of determination, R2 = 0.93) across the years.
The number of breast cancer deaths and the number of
total deaths for the 7 periods in the study are shown in
Table 3 at different time of follow-up.
The 5-, 10-, 15-, and 20- year CSS by period of diagnosis,
estimates by the lognormal model and the non-paramet-
ric Kaplan-Meier method if applicable are shown in Table
4. The standard errors were less than 4%. For patients
diagnosed in 1975–77, the 5-year CSS was 18% and 20-
year CSS was 9%. In the modern era, 1993–95, the 5-year
CSS increased to 29% and 20-year CSS was estimated to
be 20%. Table 5 shows the short-term CSS comparison
obtained by the Kaplan-Meier method and the lognormal
Table 1: Parameters in the lognormal model estimations with standard errors in brackets.
Years of diagnosis Selected S Estimated M Estimated C
1975–77 0.50 1.25(0.06) 0.07(0.06)
1978–80 0.48 1.32(0.06) 0.10(0.06)
1981–83 0.48 1.37(0.06) 0.13(0.06)
1984–86 0.43 1.30(0.04) 0.15(0.05)
1987–89 0.40 1.33(0.04) 0.16(0.04)
1990–92 0.47 1.36(0.04) 0.16(0.04)
1993–95 0.39 1.33(0.03) 0.19(0.03)
S = standard deviation,
M = mean,
C = proportion cured.
Table 2: Patient characteristics.
Years of diagnosis 1975–77 1978–80 1981–83 1984–86 1987–89 1990–92 1993–95
No. of patients 134 145 181 210 258 340 416
Race:
W h i t e 1 1 71 2 41 6 21 8 42 0 72 7 63 5 2
Black 16 15 9 19 37 49 40
O t h e r s 16871 3 1 5 2 4
U n k n o w n 0020100
Age:
Median 58 56 60 56 55 59 56
Range 26–97 29–91 22–89 25–91 25–101 34–94 26–97
Stage:
L o c a l i z e d 6361155
Regional 84 100 101 41 27 20 21
Distant 35 37 72 161 218 304 385
U n s t a g e d 95271 2 1 1 5BMC Cancer 2005, 5:137 http://www.biomedcentral.com/1471-2407/5/137
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Table 3: Number of deaths due to breast cancer and number of total deaths at six-month intervals for the 7 periods of diagnosis.
1975–77 1978–80 1981–83 1984–86 1987–89 1990–92 1993–95
Interval BCD TD BCD TD BCD TD BCD TD BCD TD BCD TD BCD TD
0 – 6 2 52 6 1 51 9 1 92 2 2 12 6 2 32 8 2 93 6 3 54 7
6–12 15 20 15 18 15 22 27 32 27 29 47 51 49 52
12–18 12 16 26 28 24 26 31 31 37 40 41 46 44 49
18–24 13 15 10 12 14 14 15 17 27 30 31 36 38 38
24–30 13 13 11 11 11 13 15 16 14 15 23 26 33 34
30–36 6 6 7 8 16 16 15 16 18 20 11 15 24 30
3 6 – 4 2 4 6 8 9 7 9 9 1 1 1 51 5 1 11 2 1 11 3
4 2 – 4 811 45 79 56 91 3 89 1 5 1 7
4 8 – 5 477 44 33 34 55 79 1 5 1 6
5 4 – 6 046 23 55 34 22 67 1 1 1 2
6 0 – 6 611 33 23 33 44 56 45
6 6 – 7 211 11 12 44 44 1 1 1 2 46
7 2 – 7 811 13 33 22 34 67 15
7 8 – 8 400 02 12 33 01 01 22
8 4 – 9 011 01 13 22 11 00 22
9 0 – 9 611 11 12 11 35 15 00
9 6 – 1 0 2 0 00 00 01 12 32 5
1 0 2 – 1 0 8 11 11 11 01 00 11
1 0 8 – 1 1 4 12 11 11 00 12 11
1 1 4 – 1 2 0 00 00 11 12 00 01
1 2 0 – 1 2 6 00 00 11 00 00 00
1 2 6 – 1 3 2 00 00 00 00 01 00
132–138 0 1 1 1 0 0 1 2 1 2
138–144 0 0 0 1 0 0 1 2 0 1
144–150 0 0 0 0 0 1 0 0 0 2
150–156 0 0 0 1 0 1 0 1 0 1
156–162 1 1 1 1 1 3 0 0 0 0
162–168 0 0 1 1 0 2 1 1
168–174 0 0 0 0 1 2 0 1
174–180 0 0 1 1 1 1 0 2
180–186 1 1 0 0 0 0 0 1
186–192 0 0 0 0 0 0 0 0
192–198 0 0 0 0 0 0 0 0
198–204 0 0 0 1 0 1 0 0
204–210 0 0 0 0 0 0
210–216 0 0 0 0 0 0
216–222 0 0 0 0 0 0
222–228 0 0 0 0 0 0
228–234 0 0 0 0 0 0
234–240 0 2 0 0
240–246 0 0 0 2
246–252 0 0 0 1
252–258 0 0 0 0
258–264 0 0 0 1
264–270 0 0 0 0
270–276 0 0 0 0
276–282 0 1
282–288 0 0
288–294 0 0
294–300 0 0
300–306 0 0
306–312 0 0
BCD = breast cancer deaths
TD = total deathsBMC Cancer 2005, 5:137 http://www.biomedcentral.com/1471-2407/5/137
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model. Figures 1, 2, 3, 4, 5, 6, 7 show both lognormal
model estimations and Kaplan-Meier curves for the differ-
ent periods.
Discussion
IBC and its outcome after treatment
IBC is a distinct entity different from the usual locally
advanced breast cancer. Chang et al. [19] studied the inci-
dence of IBC in the SEER database. IBC patients were sig-
nificantly younger at diagnosis than non-IBC patients.
Among both IBC and non-IBC patients, African Ameri-
cans were younger than whites. Overall survivals (OS)
were significantly worse for IBC patients than for non-IBC
patients and for African Americans than for whites.
Among whites, the 3-year survival improved more for IBC
patients than for non-IBC patients between 1975–1979
and 1988–1992, increasing from 32% to 42% for IBC
patients (P = 0.0001) and from 80% to 85% for non-IBC
patients (P = 0.0001).
Low  et al. [20] compared IBC versus non-IBC among
patients in the National Cancer Institute. The 46 IBC
patients had a median overall survival of 3.8 years and
event free survival of 2.3 years, compared with 12.2 and
9.0 years, respectively, in stage IIIA breast cancer patients.
Fifteen-year OS survival was 20% for IBC versus 50% for
stage IIIA patients and 23% for stage IIIB non-IBC
patients.
Table 6[3,6,21-28] summarizes the key results in research
for IBC. Chang et al. [22] evaluated the effects of obesity
and menopausal status on survival in a cohort of 177
female IBC patients diagnosed between 1974 and 1993.
They found that factors associated with larger body size at
Table 4: 5-, 10-, 15- and 20-year cause-specific survival (CSS) rates, in percentages, estimated by Kaplan-Meier method compared with 
those estimated by lognormal model [in square brackets] with 95% confidence intervals (in round brackets).
Years of 
diagnosis
5 yr CSS 10 yr CSS 15 yr CSS 20 yr CSS
1975–77 18(16.5–19.4), [20](18.4–21.5) 11(10.3–11.6), [11](10.3–11.6) 9(8.4–9.5), [9](8.4–9.5) 9(8.4–9.5), [8](7.5–8.4)
1978–80 23(21.1–24.8), [24](22.1–25.8) 16(15.0–16.9), [14](13.1–14.8) 11(10.3–11.6), [12](11.2–12.7) 11(10.3–11.6), [11](10.3–11.6)
1981–83 27(24.8–29.1), [30](27.6–32.2) 18(16.9–19.0), [19](17.8–20.1) 14(13.1–14.8), [15](14.1–15.8) NA, [14](13.1–14.8)
1984–86 27(25.4–28.5), [26](24.4–27.5) 17(16.0–17.9), [18](16.9–19.0) 15(14.1–15.8), [16](15.0–16.9) NA, [15](14.1–15.8)
1987–89 27(25.4–28.5), [27](25.4–28.5) 19(17.8–20.1), [18](16.9–19.0) NA, [16](15.0–16.9) NA, [16](15.0–16.9)
1990–92 32(30.1–33.8), [32](30.1–33.8) 21(19.7–22.2), [22](20.7–23.2) NA, [19](17.8–20.1) NA, [18](16.9–19.0)
1993–95 29(27.8–30.1), [29](27.8–30.1) NA, [21](19.7–22.2) NA, [20](18.8–21.1) NA, [20](18.8–21.1)
NA = not available by Kaplan-Meier method
Table 5: 0.5-, 1-, 2-, 3- and 4-year cause-specific survival (CSS) rates, in percentages, estimated by Kaplan-Meier method compared 
with those estimated by lognormal model [in square brackets] with 95% confidence intervals (in round brackets).
Years of diagnosis 0.5 yr CSS 1 yr CSS 2 yr CSS 3 yr CSS 4 yr CSS
1975–77 81(76.2–85.7), 
[84](79.0–88.9)
70(64.5–75.4), 
[66](60.8–71.1)
49(45.1–52.8), 
[44](40.5–47.4)
33(30.4–35.5), 
[32](29.4–34.5)
28(25.8–30.1), 
[25](23.0–26.9)
1978–80 89(83.7–94.2), 
[89](83.7–94.2)
79(74.3–83.6), 
[73](68.7–77.2)
52(47.9–56.0), 
[51](47.0–54.9)
38(35.0–40.9), 
[38](35.0–40.9)
28(25.8–30.1), 
[30](27.6–32.3)
1981–83 89(85.5–92.4), 
[90](86.4–93.5)
81(76.2–85.7), 
[76](71.5–80.4)
58(53.4–62.5), 
[55](50.6–59.3)
41(37.7–44.2), 
[43](39.6–46.3)
32(29.4–34.5), 
[35](32.2–37.7)
1984–86 90(86.4–93.5), 
[90](86.4–93.5)
77(72.4–81.5), 
[74](69.6–78.3)
53(48.8–57.1), 
[51](47.0–54.9)
38(35.7–40.2), 
[39](36.7–41.2)
30(28.2–31.7), 
[31](29.1–32.8)
1987–89 91(87.4–94.5), 
[91](87.4–94.5)
80(75.2–84.7), 
[77](72.4–81.5)
54(50.8–57.1), 
[53](49.8–56.1)
41(38.5–43.4), 
[40](37.6–42.3)
31(29.1–32.8), 
[32](30.1–33.8)
1990–92 91(87.4–94.5), 
[90](86.4–93.5)
77(73.9–80.0), 
[77](73.9–80.0)
54(50.8–57.1), 
[57](53.6–60.3)
43(40.4–45.5), 
[45](42.3–47.6)
37(34.8–39.1), 
[37](34.8–39.1)
1993–95 91(89.2–92.7), 
[92](90.1–93.8)
79(75.9–82.0), 
[79](75.9–82.0)
58(55.7–60.2), 
[56](53.8–58.1)
44(41.4–46.5), 
[42](39.5–44.4)
36(34.5–37.4), 
[34](32.6–35.3)BMC Cancer 2005, 5:137 http://www.biomedcentral.com/1471-2407/5/137
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diagnosis may contribute to shorter survival among post-
menopausal IBC women but not among pre-menopausal
IBC women. The latter were found to have poor survival
regardless of body size.
In the table of patient characteristics (Table 2) of the dif-
ferent periods, the age distributions are similar for the dif-
ferent periods. However, the earlier 3 periods have similar
stage distribution, and the later 4 periods have another
similar stage distribution, with more distant stage patients
compared with the earlier 3 periods. Despite an increasing
proportion of distant stage, survival is increasing. This
likely reflects the vigilance of staging investigations in
recent time periods.
The present study shows a gradual increase in CSS rate
over time, for both the Kaplan-Meier method and the log-
normal model. The estimations of the long-term CSS rates
Fitting of the lognormal model estimation to the Kaplan- Meier curve for 1975–1977 Figure 1
Fitting of the lognormal model estimation to the Kaplan-
Meier curve for 1975–1977.
Fitting of the lognormal model estimation to the Kaplan- Meier curve for 1978–1980 Figure 2
Fitting of the lognormal model estimation to the Kaplan-
Meier curve for 1978–1980.
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Fitting of the lognormal model estimation to the Kaplan- Meier curve for 1981–1983 Figure 3
Fitting of the lognormal model estimation to the Kaplan-
Meier curve for 1981–1983.
Fitting of the lognormal model estimation to the Kaplan- Meier curve for 1984–1986 Figure 4
Fitting of the lognormal model estimation to the Kaplan-
Meier curve for 1984–1986.
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by the lognormal model for 1975–77 and 1978–80 were
validated within one standard error of those rates calcu-
lated by using Kaplan-Meier method. The above results
show what is achievable in different institutions over a
wide area of United States. Published single institution
studies from major or tertiary referral centers do not
reflect the true picture of care in the community. The long-
term CSS calculated by the lognormal model for the
cohort diagnosed in the years 1993–1995 is stable at 20%.
There is little further drop of CSS beyond 10 years. The
improvement in survival has been achieved by years of
research, as noted below.
Perez et al. [23] analyzed 179 patients with histologically
confirmed inflammatory carcinoma of the breast. Mini-
mum follow-up was 2 years (maximum, 12 years; median,
4 years in the surviving patients). Clearly better loco-
regional tumor control, i.e. in the breast and regional
nodal drainage area, was observed in patients who under-
went a surgical procedure: 79% with three modalities,
76% with irradiation and surgery, and only 30% with irra-
diation alone or in combination with chemotherapy. The
addition of mastectomy to irradiation significantly
improved loco-regional tumor control, disease free sur-
vival (DFS), and CSS. The combination of chemotherapy,
surgery, and irradiation had a significant impact on loco-
regional tumor control and incidence of distant metas-
tases compared with surgery plus irradiation, and a lesser
impact on DFS and CSS.
The literature indicates that chemotherapy does not
negate the importance of radiation in optimizing loco-
regional control in patients with high-risk breast cancer.
The results of recent randomized trials studying postmas-
tectomy radiation show that improved loco-regional con-
trol improves OS. Thus many authors believe that all
breast cancer patients who have high-risk primary breast
cancer and who are treated with chemotherapy should
receive radiation as a component of their treatment [26].
Liao et al. [27] studied 115 patients with nonmetastatic
IBC and tested the use of twice a day (b.i.d.) radiotherapy
Fitting of the lognormal model estimation to the Kaplan- Meier curve for 1987–1989 Figure 5
Fitting of the lognormal model estimation to the Kaplan-
Meier curve for 1987–1989.
Fitting of the lognormal model estimation to the Kaplan- Meier curve for 1990–1992 Figure 6
Fitting of the lognormal model estimation to the Kaplan-
Meier curve for 1990–1992.
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Fitting of the lognormal model estimation to the Kaplan- Meier curve for 1993–1995 Figure 7
Fitting of the lognormal model estimation to the Kaplan-
Meier curve for 1993–1995.
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treatment with total dose of 60 Gy and 66 Gy at different
time periods. Accelerated, b.i.d. fractionation at 1.5 Gy
per fraction to a dose of 45 Gy plus 15 Gy chest wall boost
was used for most patients from 1982 to 1985. From
1986–1993, 51 Gy in 34 fractions was delivered over 17
treatment days, followed by a 15 Gy chest wall boost in 10
fractions over a period of 5 treatment days. Chemother-
apy regimens used did not change significantly during the
period of that study. Long-term complications of
radiation, such as arm edema of more than 3 cm (in 7
patients), rib fracture (in 10 patients), severe chest wall
fibrosis (in 4 patients), and symptomatic pneumonitis (in
5 patients), were comparable in the two groups of 60 Gy
versus 66 Gy, indicating that the dose escalation did not
result in increased morbidity. Significant differences in
the rates of loco-regional control (P = 0.03) and OS (P =
0.03), and a trend towards better DFS (P = 0.06) were
observed among those recently treated patients who
received higher doses of irradiation. For the entire patient
group who received radiotherapy either once or twice
daily, the 5- and 10-year local control rates were 73.2%
and 67.1%, respectively. The 5- and 10-year DFS were
32.0% and 28.8%, respectively, and the overall survival
rates for the entire group were 40.5% and 31.3%,
respectively.
In France, a study on the impact of intensity of chemo-
therapy was performed [28] on 74 women with
nonmetastatic IBC consecutively treated between 1976
and 2000. Patients received primary anthracycline-based
chemotherapy either at conventional doses (n = 20) or at
high does with hematopoietic stem cell support (HSCS)
(n = 54). In multivariate analysis, the strongest independ-
ent prognostic factor was the delivery of high-dose chem-
otherapy (HDC). The 5-year DFS and OS of patients were
respectively 28% and 50% with HDC and 15% and 18%
with conventional chemotherapy. These results suggest
that HDC with HSCS may have a role in the treatment of
IBC.
Recent study on the use of trastuzumab and paclitaxel
may well lead to further research on the use of different
combinations of chemotherapy and biological response
modifiers [29] for the treatment of IBC. After completion
of chemotherapy, for patients whose tumors showed
receptor-positive tumors; additional tamoxifen therapy (if
post-menopausal) or gonadotropin-releasing hormone
(GnRH)-analogues (if pre-menopausal) were given. How-
ever, it is still uncertain, whether better prognosis can be
achieved by treatment with GnRH-analogues [30].
Ueno et al. [6] found from the long-term follow-up data
on patients treated with a combined-modality
(chemotherapy, then mastectomy, then chemotherapy
and radiotherapy) approach, a significant fraction of
patients (estimated to be 28%) remained free of disease
beyond 15 years. There were virtually no recurrences after
10 years. Estimated DFS at 5 years was 32%, at 10 years
Table 6: Summary of key findings in research for inflammatory breast cancer.
Author Ref. Institute Year Patient No. Main results
Palangie [21] Institut Curie, France 1977–1987 223 Better DFS – rapid and complete remission with induction 
treatment
Chang [22] MD Anderson, US 1974–1993 177 Shorter OS – for postmenopausal IBC women with larger body 
size
Liauw [3] U. Florida, US 1982–2001 61 Improved CSS – tumor size <4 cm, upfront surgery, local disease 
control
Perez [23] Mallinckrodt, US 1958–1989 179 Improved DFS, CSS, LR – addition of mastectomy
Panades [24] British Columbia, Canada 1980–2000 485 Improved LC – mastectomy in addition to chemotherapy and 
radiotherapy
Improved CSS – modern chemotherapy regimens
Fleming [25] MD Anderson, US 1974–1993 178 Improved LC – mastectomy in addition to radiotherapy 16.3% vs 
35.7%, P = 0.015
Buchholz [26] MD Anderson, US 1989–1997 12 Chemotherapy with radiation improved OS
Liao [27] MD Anderson, US 1977–1993 115 Improved LC, DFS, OS – twice-daily postmastectomy radiation to 
66 Gy
Bertucci [28] Institut Paoli-Calmettes, France 1976–2000 74 High-dose chemotherapy: 5y DFS 28%, OS 50% Conventional dose 
chemotherapy: 5y DFS 15%, OS 18%
Ueno [6] MD Anderson, US 1973–1993 178 Improved DFS – combined modality: 15y DFS 28%, single-modality: 
15y DFS <5%
DFS = disease free survival,
OS = overall survival,
CSS = cause-specific survival,
LC = local recurrence.BMC Cancer 2005, 5:137 http://www.biomedcentral.com/1471-2407/5/137
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was 28%, and at 15 years was 28%. Estimated OS at 5
years was 40%, at 10 years was 33%, and at 15 years was
29%. By contrast, single-modality treatment
(radiotherapy or surgery alone) gave a DFS of less than 5%
beyond 15 years. Thus, combined-modality treatment is
recommended as the standard of care for IBC.
Possible explanations to the improved survival
IBC is a distinct clinicopathologic entity separate from
noninflammatory locally advanced breast carcinoma
[31,32]. Improvements in population-based survival
represent the extent to which therapies with demonstrated
efficacy are translated to the real population. Thus, they
represent the effect of dissemination of new therapies and
effectiveness. In the early 1970s, the commonly used reg-
imen was FAC (5-fluorouracil, adriamycin,
cyclophosphamide) before and after radiotherapy. In the
late 1970s, FAC was given before and after mastectomy
[6]. Taxanes become increasingly used in America since
2001 [33].
There are several other possible explanations to the
improved survival other than treatment changes: change
of the definition and classification of IBC, proportion of
cause specific deaths not based on autopsy, change of
patient population (age distribution, stages [IIIB and IV]).
Obesity is a poor prognostic factor and so the improve-
ment of IBC survival is not related to increasing obesity
noted in the American population. Better treatment and
the above factors all account for the improved survival.
Conclusion
The improvement of survival during the study period may
be due to introduction of more aggressive treatments.
However, there seem to be no further increase of long-
term CSS, which should encourage oncologists to find
even more effective treatments. Because of small numbers
of patients, randomized studies will be difficult to
conduct. The SEER population-based database will yield
the best possible estimate of the trend in improvement of
survival for patients with IBC.
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